Temodex developers

Double-L is a Belarusian pharmaceutical company specializing in the development and production of innovative drug delivery systems, most notably the hydrogel-based chemotherapy Temodex. Developed in collaboration with the Research Institute for Physical and Chemical Problems of the Belarusian State University, Temodex is a local chemotherapy treatment for glioblastoma multiforme that is applied directly to the tumor bed after surgical resection. The company's technology platform utilizes biocompatible polymers to provide sustained release of active pharmaceutical ingredients, aiming to reduce recurrence and improve survival rates in oncology. Double-L's portfolio also includes other hydrogel-based treatments like Prospidex for head and neck cancers. The company operates manufacturing facilities in Minsk and primarily serves the healthcare markets in Belarus and the CIS region.